Larimar Therapeutics Inc (OQ:LRMR)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Tel: N/A
IR: See website
Key People
Carole S. Ben-Maimon
President, Chief Executive Officer, Director
Michael Celano
Chief Financial Officer, Company Secretary
Russell G. Clayton
Chief Medical Officer
Gopi Shankar
Chief Development Officer
Business Overview
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its cell penetrating peptide (CPP) technology platform. The Company's lead compound, CTI-1601, is being developed as a potential treatment for Friedreichs ataxia (FA). CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with FA. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient frataxin (FXN) due to a genetic abnormality. It also focuses on using its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Its CPP platform enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets.
Financial Overview
For the nine months ended 30 September 2023, Larimar Therapeutics Inc revenues was not reported. Net loss decreased 8% to $24M. Lower net loss reflects Other income, net increase from $157K to $3.6M (income), Research and Development decrease of 2% to $14.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.33 to -$0.55.
Employees: 26 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $59.84M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$37.66M as of Sep 30, 2023
Net annual income (TTM): -$33.38M as of Sep 30, 2023
Free cash flow (TTM): -$30.79M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 43,905,903 as of Nov 12, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.